A new class of medicines harnessing IL-22 biology to better treat metabolic diseaseLearn about our Science

About Cytoki Pharma

Cytoki Pharma (Cytoki) is a clinical-stage biotechnology company pioneering a new class of medicines that harness the innate biology of IL-22 to address metabolic diseases, including obesity and type 2 diabetes, and conditions characterized by epithelial injury, such as inflammatory bowel disease. CK-0045, our lead, long-acting IL-22 analog, is currently undergoing Phase 1 clinical evaluation to assess safety and tolerability in healthy participants with and without obesity, with results anticipated in the first half of 2024. Cytoki was founded in 2019 after licensing of a full IL-22 analogue program from Novo Nordisk.

Learn about Cytoki